NCT02584933
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02584933
Title Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | POL | LBN | ITA | FRA | ESP | DEU | CZE | BRA | BGR | BEL | AUS

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Loma Linda University Loma Linda California 92354 United States Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Maryland Oncology Hematology P A Rockville Maryland 20850 United States Details
Essex Oncology of North Jersey PA Belleville New Jersey 07109 United States Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Auckland 1023 Australia Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Natal Rio Grande do Norte 59075 740 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande do Sul 90610-000 Brazil Details
Novartis Investigative Site Barretos São Paulo 14784 400 Brazil Details
Novartis Investigative Site São Paulo São Paulo 01246 000 Brazil Details
Novartis Investigative Site Sofia 1303 Bulgaria Details
Novartis Investigative Site Guangzhou Guangdong 510080 China Details
Novartis Investigative Site Guangzhou Guangdong 510120 China Details
Novartis Investigative Site Changchun Jilin 130012 China Details
Novartis Investigative Site Beijing 100039 China Details
Novartis Investigative Site Guangzhou 510060 China Details
Novartis Investigative Site Montería 230004 Colombia Details
Novartis Investigative Site Brno 656 53 Czechia Details
Novartis Investigative Site Paris 75231 France Details
Novartis Investigative Site Paris 75970 France Details
Novartis Investigative Site Saint-Herblain 44805 France Details
Novartis Investigative Site Strasbourg 67091 France Details
Novartis Investigative Site Villejuif 94800 France Details
Novartis Investigative Site Regensburg Bavaria 93053 Germany Details
Novartis Investigative Site Cologne 50937 Germany Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Würzburg 97074 Germany Details
Novartis Investigative Site Hong Kong 999077 Hong Kong Details
Novartis Investigative Site Pokfulam 999077 Hong Kong Details
Novartis Investigative Site Bergamo BG 24127 Italy Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Brescia BS 25123 Italy Details
Novartis Investigative Site Meldola FC 47014 Italy Details
Novartis Investigative Site Monza MB 20900 Italy Details
Novartis Investigative Site Milan MI 20133 Italy Details
Novartis Investigative Site Milan MI 20141 Italy Details
Novartis Investigative Site Milan MI 20162 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Modena MO 41124 Italy Details
Novartis Investigative Site Perugia PG 06129 Italy Details
Novartis Investigative Site Aviano PN 33081 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Novara 28100 Italy Details
Novartis Investigative Site Nagoya Aichi-ken 464 8681 Japan Details
Novartis Investigative Site Fukuoka Fukuoka 811-1395 Japan Details
Novartis Investigative Site Akashi Hyōgo 673-8558 Japan Details
Novartis Investigative Site Koto Ku Tokyo 135 8550 Japan Details
Novartis Investigative Site Beirut 166830 Lebanon Details
Novartis Investigative Site George Town Pulau Pinang 10450 Malaysia Details
Novartis Investigative Site Kuching Sarawak 93586 Malaysia Details
Novartis Investigative Site Gdansk 80 952 Poland Details
Novartis Investigative Site Moscow 115522 Russia Details
Novartis Investigative Site Saint Petersburg 192148 Russia Details
Novartis Investigative Site Saint Petersburg 197343 Russia Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seoul 03722 South Korea Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site Barcelona Catalonia 08035 Spain Details
Novartis Investigative Site A Coruña 15006 Spain Details
Novartis Investigative Site Madrid 28046 Spain Details
Novartis Investigative Site Madrid 28050 Spain Details
Novartis Investigative Site Málaga 29010 Spain Details
Novartis Investigative Site Taichung 40447 Taiwan Details
Novartis Investigative Site Taichung 407219 Taiwan Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Taipei 110 Taiwan Details
Novartis Investigative Site Taipei 11217 Taiwan Details
Novartis Investigative Site Taoyuan District 33305 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field